GSK to acquire Affinivax for MAPS vaccine platform
GSK will pay up to $3.3 billion to acquire Affinivax, gaining access to its Multiple Antigen Presenting System (MAPS) technology and pneumococcal vaccine candidates.
List view / Grid view
GSK will pay up to $3.3 billion to acquire Affinivax, gaining access to its Multiple Antigen Presenting System (MAPS) technology and pneumococcal vaccine candidates.
Pfizer reveals co-administering its Prevnar 20™ pneumococcal vaccine and a booster dose of Comirnaty® COVID-19 vaccine was safe and immunogenic.
MenQuadfi® has been approved for use in individuals 12 months of age and older, based on its safety and immunogenicity in 6,300 trial subjects.
The trial will assess the safety, tolerability and immunogenicity of the five-in-one MenABCWY vaccine in participants aged 10 to 25.
The EMA has announced the results of its pharmacovigilance meeting for March, saying that it has started a review of medicines containing ifosfamide due to a higher risk of encephalopathy.
29 June 2016 | By Victoria White, Digital Content Producer
GlobalData says MenABCWY has the potential to significantly change the approach used to prevent meningococcal disease...
7 June 2016 | By Victoria White, Digital Content Producer
The meningococcal vaccines market is expected to grow from around $1.1 billion in 2015 to $1.8 billion by 2025, according to GlobalData...
13 May 2016 | By Victoria White, Digital Content Producer
Pfizer has announced results of two Phase III studies demonstrating the immunogenicity of Trumenba against invasive meningococcal B strains...
9 March 2016 | By GlobalData
The UK Department of Health’s rejection of a petition to expand the routine administration of MenB vaccine Bexsero may lead to parents and physicians to consider purchasing the vaccine themselves...
28 July 2015 | By Victoria White
Four public health organisations have warned of acute shortages of meningitis C-containing vaccine as the risk of a meningitis C outbreak in Africa grows...
22 June 2015 | By Victoria White
Pfizer has entered into an agreement with GlaxoSmithKline to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for $130 million...